BAVARIAN NORDIC
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1992-01-01
- Employees
- 759
- Market Cap
- $3.1B
Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 165
- Registration Number
- NCT00189956
- Locations
- 🇨ðŸ‡
Swiss Pharma Contract, Basel, Switzerland
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 151
- Registration Number
- NCT00189904
- Locations
- 🇺🇸
Vanderbilt AIDS Clinical Trials Center, Nashville, Tennessee, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 120
- Registration Number
- NCT00078585
- Locations
- 🇺🇸
San Diego Urology Center, La Mesa, California, United States
🇺🇸Urology Associates of Central California, Fresno, California, United States
🇺🇸Western Clinical Research, Inc., Torrance, California, United States
© Copyright 2024. All Rights Reserved by MedPath